Full results from PEDFIC 1, the first and largest, global, Phase 3 study ever conducted in PFIC, confirm both U.S. and EU primary endpoints were met in the randomized, double-blind, placebo-controlled trial. BOSTON, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel … Forward-looking statements include statements, other than statements of historical fact, regarding, among other things: the plans for, or progress, scope, cost, initiation, duration, enrollment, results or timing for availability of results of, development of odevixibat or any other Albireo product candidate or program, including regarding expectations regarding the impact of COVID-19 on our business and our ability to adapt our approach as appropriate; the Phase 3 clinical program for odevixibat in patients with PFIC, the pivotal trial for odevixibat in biliary atresia (BOLD), and the planned pivotal trial for odevixibat in Alagille syndrome; the target indication(s) for development or approval, the size, design, population, location, conduct, cost, objective, enrollment, duration or endpoints of any clinical trial, or the timing for initiation or completion of or availability or reporting of results from any clinical trial, including the long-term open-label extension study for odevixibat in PFIC, the pivotal trial for odevixibat in biliary atresia, the planned pivotal trial for odevixibat in Alagille syndrome; the potential approval and commercialization of odevixibat; discussions with the FDA or EMA regarding our programs; the potential benefits or competitive position of odevixibat or any other Albireo product candidate or program or the commercial opportunity in any target indication; the potential effects of odevixibat of the treatment of PFIC patients and its potential to improve the current standard of care; the potential benefits of an orphan drug designation; the potential issuance of a rare pediatric disease priority review voucher; or Albireo’s plans, expectations or future operations, financial position, revenues, costs or expenses. Albireo often uses words such as “anticipates,” “believes,” “plans,” “expects,” “projects,” “future,” “intends,” “may,” “will,” “should,” “could,” “estimates,” “predicts,” “potential,” “planned,” “continue,” “guidance,” and similar expressions to identify forward-looking statements. Other symptoms include jaundice, poor weight gain and slowed growth. About Biliary AtresiaBiliary atresia is a rare pediatric liver disease with symptoms typically developing about two to eight weeks after birth. The Company expects to complete IND-enabling studies for new preclinical candidate A3907 this year and plans to advance development in adult liver disease. Currently, there are no approved drug treatments. Albireo was spun out from AstraZeneca in 2008. There are no drugs currently approved for PFIC, only surgical options that include partial external biliary diversion (PEBD) and liver transplantation. BOSTON, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. ... any forward-looking statement in this press release represents Albireo’s views only as of the date of this press release … 3, 2020 at 7:39 a.m. Albireo Pharma stock price target cut to $60 from $69 at Wedbush Mar. Albireo Launches Expanded Access Program for Odevixibat for Patients in the U.. Albireo Enrolls First Patient in Phase 3 Clinical Trial of Odevixibat in Bili.. Albireo to Host Key Opinion Leader Call on Clinical Outcome Assessments. Looking back to 2 days ago, Albireo Pharma Inc (ALBO) priced a 4,000,000 share secondary stock offering at $40.00 per share. Company profile page for Albireo Pharma Inc including stock price, company news, press releases, executives, board members, and contact information Albireo Pharma, Inc. (NASDAQ: ALBO) Q4 2018 Earnings Conference Call ... Albireo issued a press release highlighting recent business accomplishments and … Albireo is developing novel bile acid modulators to treat rare pediatric and adult liver diseases. For more information on Albireo, please visit www.albireopharma.com. BOSTON, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced it … In addition to PFIC, odevixibat has Orphan Drug Designations for the treatment of Alagille Syndrome, biliary atresia and primary biliary cholangitis. With FDA and EMA regulatory submissions complete, odevixibat has the potential to become the first approved drug treatment for patients with PFIC in the U.S and Europe. Albireo is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders. Find the latest press releases from Albireo Pharma, Inc. Common Stock (ALBO) at Nasdaq.com. About Alagille SyndromeAlagille Syndrome (ALGS) is a rare multisystem genetic disorder that can affect the liver, heart, skeleton, eyes, central nervous system, kidneys, and facial features. Albireo to Announce Topline Results from PEDFIC 1 Phase 3 Trial of Odevixibat.. Albireo Reports Topline Results from Phase 2 Trial of Elobixibat in NAFLD/NAS.. Albireo Reports Q2 2020 Financial Results and Provides Business Update, Albireo to Present at the William Blair Biotech Focus Conference 2020, Albireo to Report Q2 2020 Financial Results on August 6. BOSTON, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) and a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) seeking approval of odevixibat for the treatment of patients with progressive familial intrahepatic cholestasis (PFIC). Actual results, performance or experience may differ materially from those expressed or implied by any forward-looking statement as a result of various risks, uncertainties and other factors, including, but not limited to: negative impacts of the COVID-19 pandemic, including on manufacturing, supply, conduct or initiation of clinical trials, or other aspects of our business; whether favorable findings from clinical trials of odevixibat to date, including findings in indications other than PFIC, will be predictive of results from other clinical trials of odevixibat; whether either or both of the FDA and EMA will determine that the primary endpoint for their respective evaluations and treatment duration of the double-blind Phase 3 trial in patients with PFIC are sufficient to support approval of odevixibat in the United States or the European Union, to treat PFIC, a symptom of PFIC, a specific PFIC subtype(s) or otherwise; the outcome and interpretation by regulatory authorities of the ongoing third-party study pooling and analyzing of long-term PFIC patient data; the timing for initiation or completion of, or for availability of data from, clinical trials of odevixibat, including the pivotal program in biliary atresia or the planned pivotal program in Alagille syndrome, and the outcomes of such trials; Albireo’s ability to obtain coverage, pricing or reimbursement for approved products in the United States or European Union; delays or other challenges in the recruitment of patients for, or the conduct of, company’s clinical trials; and Albireo’s critical accounting policies. Phase 3 data was recently presented at the AASLD that showed a durable response to odevixibat in patients with PFIC. Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today that … Albireo Announces Two Financing Transactions to Extend Cash Runway Into the B.. Albireo to Present at 2020 Jefferies Virtual Healthcare Conference, Albireo Reports Q1 2020 Financial Results and Provides Business Update, Albireo to Report First Quarter 2020 Financial Results on May 7, Albireo to Present at 19th Annual Needham Healthcare Conference, Albireo Completes Enrollment in Phase 2 Study of Elobixibat in NASH/NAFLD. The EMA’s Pediatric Committee has agreed to Albireo’s odevixibat Pediatric Investigation Plans for PFIC and biliary atresia. “We are grateful to the patients, families and investigators for their involvement in our mission to bring hope to families and reduce disease burden. Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that … In addition, any forward-looking statement in this press release represents Albireo’s views only as of the date of this press release and should not be relied upon as representing its views as of any subsequent date. Albireo Reports Fourth Quarter and Year-End 2019 Financial Results, and Provi.. Albireo Recognizes Rare Disease Day and Supports Global Effort to “Refr.. Albireo to Present at Cowen and Company 40th Annual Health Care Conference. Odevixibat is a potent, once-daily, non-systemic ileal bile acid transport inhibitor (IBATi) being developed to treat rare pediatric cholestatic liver diseases, including PFIC, biliary atresia and Alagille syndrome. Across both studies, odevixibat was generally well tolerated, and treatment-emergent adverse events (TEAEs) were mostly mild or moderate. BOSTON, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, joins the PFIC Advocacy and Resource Network (PFIC Network) in recognition of PFIC Awareness Day 2020, a global effort to support patients and families affected by progressive familial intrahepatic cholestasis … Albireo to Report Fourth Quarter and Year-End 2019 Financial Results on March.. Albireo Announces Closing of $46 Million Public Offering Including Exercise i.. Albireo Announces Proposed Public Offering of Common Stock. A potent, once-daily, non-systemic ileal bile acid transport inhibitor (IBATi), odevixibat acts locally in the small intestine. Patients have impaired bile flow, or cholestasis, caused by genetic mutations. Children have clay-colored or no color in their stools, jaundice among other things and a few patients are pruritic. © 2020 GlobeNewswire, Inc. All Rights Reserved. ALBIREO PHARMA, INC. : Press releases relating to ALBIREO PHARMA, INC. Investor relations | Nasdaq: ALBO | Nasdaq “With randomized, placebo-controlled PEDFIC data, Orphan Designations in both the U.S. and EU, accelerated assessment and access to the PRIME scheme in the EU and Fast Track designation in the U.S., we’re on track for potential approval, launch and broad global access to odevixibat for PFIC patients in the second half of 2021.”. The EMA has granted odevixibat accelerated assessment, Orphan Designation, as well as access to the PRIority MEdicines (PRIME) scheme for the treatment of PFIC. Upcoming event on ALBIREO PHARMA, INC. 11/17/20: Q3 2020 Earnings Release (Projected) Company calendar As a result of risks and uncertainties that Albireo faces, the results or events indicated by any forward-looking statement may not occur. Positive results from the trial were announced on September 8, 2020: News Release – Albireo Phase 3 Trial Meets Both Primary Endpoints for Odevixibat in PFIC. Initiation of a pivotal Phase 3 trial of odevixibat for Alagille syndrome is also anticipated by the end of 2020. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. ET by Tomi Kilgore Albireo Pharma stock price target cut to $32 from $36 at Ladenburg Thalmann About AlbireoAlbireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders. BOSTON, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel … About Albireo Who We Are. Damaged or absent bile ducts outside the liver result in bile and bile acids being trapped inside the liver, quickly resulting in cirrhosis, and even liver failure. About Biliary Atresia. Albireo cautions you not to place undue reliance on any forward-looking statement. - Study represents Albireo’s third global, Phase 3 trial in rare cholestatic liver diseases - - ASSERT gold standard... | December 17, 2020 The Company also provides an Expanded Access Program for eligible patients with PFIC in the U.S., Canada, Australia and Europe. In many cases, PFIC leads to cirrhosis and liver failure within the first 10 years of life, and nearly all people with PFIC require treatment before age 30. Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that … Albireo Pharma is located in Boston, Massachusetts, and its key operating subsidiary is located in Gothenburg, Sweden. Beyond PFIC, we are poised to initiate our Phase 3 trial in Alagille syndrome by end of year, expanding our pivotal programs across three rare liver diseases.”. An Albireo Pharma news release notes that the company saw positive results from its recent Phase 3 clinical trial of odevixibat. “We have completed both the U.S. and EU regulatory submissions in record time, which speaks to the Albireo team’s commitment to providing children with different forms of PFIC a treatment option as quickly as possible,” said Ron Cooper, President and Chief Executive Officer of Albireo. Additionally, long-term data from PEDFIC 2, an open-label Phase 3 extension study, demonstrate continued and durable reductions in sBAs, improvements in pruritus assessments and encouraging markers of liver and growth function in patients treated up to 48 weeks. Positive results from the trial were announced on September 8, 2020: News Release – Albireo Phase 3 Trial Meets Both Primary Endpoints for Odevixibat in PFIC. Boston, USA-based biotech Albireo Pharma has submitted a New Drug Application (NDA) to the US Food and… To continue reading The Pharma Letter please login , subscribe or claim a 7 day free trial subscription and access exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space. Media Contact:Colleen Alabiso, 857-356-3905, colleen.alabiso@albireopharma.comLisa Rivero, 617-947-0899, lisa.rivero@syneoshealth.com, Investor Contact: Hans Vitzthum, LifeSci Advisors, LLC., 857-272-6177. Odevixibat has previously received Fast Track, Rare Pediatric Disease and Orphan Drug Designations in the U.S. Forward-Looking Statements This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. The Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment and analysis for the pharmaceutical, biotechnology and generics sectors of the health care industry, backed by a team of respected writers with many years of experience in the field. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year. Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4). Collectively, these studies reaffirm odevixibat’s potential to be the first drug treatment approved for patients living with PFIC, a devastating disease which is currently treated with surgical options including liver transplantation. Additional information on PFIC is available at https://www.pficvoices.com. Get the latest Albireo Pharma, Inc. (ALBO) stock news and headlines to help you in your trading and investing decisions. - Data on PFIC types 1, 2, 3 submitted to support use across a wide range of patients -, - EMA grants accelerated assessment, validates Marketing Authorization Application for odevixibat with orphan designation and access to PRIority MEdicines (PRIME) -, - FDA has granted odevixibat Fast Track, Rare Pediatric Disease and Orphan Drug Designations -, - Largest PFIC patient database shows improvements in quality of life measures, including growth and liver parameters observed with long-term odevixibat administration -. Biliary atresia is the most common pediatric cholestatic liver disease and is the leading cause of liver transplants among children as there are no approved drug treatments. The EMA has validated the odevixibat MAA on the accelerated assessment timeline, which begins the formal review process. Products described on this Website, with the exception of elobixibat for chronic constipation in Japan, are investigational new drugs, and are not approved for use or commercially available. Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Albireo Pharma, Inc. December 11, 2020 GMT. Biliary atresia is a rare pediatric liver disease with symptoms typically developing about two to eight weeks after birth and no approved pharmacological therapies. Press release content from Globe Newswire. Forward-Looking Statements. The most prominent and problematic ongoing manifestation of the disease is pruritus, or intense itching, which often results in a severely diminished quality of life. Albireo disclaims any obligation to update any forward-looking statement, except as required by applicable law. “With strong data from the first and largest global Phase 3 study ever conducted in PFIC, we have a comprehensive database that has the potential to influence the way PFIC is treated, the use of odevixibat and how reimbursement will be achieved,” added Cooper. Albireo Pharma (NASDAQ:ALBO): Q3 GAAP EPS of -$1.96 misses by $0.45.Revenue of $2.13M (+53.2% Y/Y) beats by $0.5M.Press Release Albireo cautions you not to place undue reliance on any forward-looking statement. This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. The Phase 3 trial of odevixibat in Alagille syndrome will be the third pivotal trial of odevixibat. These and other risks and uncertainties that Albireo faces are described in greater detail under the heading “Risk Factors” in Albireo’s most recent Annual Report on Form 10-K or in subsequent filings that it makes with the Securities and Exchange Commission. Odevixibat is currently being evaluated in the ongoing PEDFIC 2 open-label trial (NCT03659916) and the BOLD Phase 3 trial in patients with biliary atresia (NCT04336722). Phase 3 data was recently presented at the AASLD that showed a durable response to odevixibat in patients with PFIC. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) BOSTON, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the grant of inducement stock options exercisable for an aggregate of 18,500 shares of Albireo’s common stock. Detailed price information for Albireo Pharma Inc (ALBO-Q) from The Globe and Mail including charting and trades. In addition, any forward-looking statement in this press release represents Albireo’s views only as of the date of this press release and should not be relied upon as representing its views as of any subsequent date. About PFICProgressive familial intrahepatic cholestasis (PFIC) is a rare disorder that causes progressive, life-threatening liver disease. Equal Opportunity Employer. Liver damage is caused by a paucity of bile ducts preventing bile flow from the liver to the small intestine. The AP news staff was not involved in its creation. Odevixibat does not require refrigeration and can be taken as a capsule for older children, or opened and sprinkled onto food, which are factors of key importance for adherence in a pediatric patient population. Approximately 95 percent of patients with ALGS present with chronic cholestasis, usually within the first three months of life, and up to 88 percent also present with severe, intractable pruritus. A high-level overview of Albireo Pharma, Inc. (ALBO) stock. Albireo Submits for U.S. FDA and EMA Product Approval of Once-Daily Odevixiba.. New Phase 3 Data at AASLD Show Durable Response to Odevixibat in a Rare Pedia.. Albireo to Participate in Jefferies and Piper Sandler Virtual Investor Confer.. Albireo Reports Q3 2020 Financial Results and Provides Business Update, Albireo's Odevixibat PFIC Phase 3 Results Accepted for AASLD Late-Breakers, Albireo Announces Presentations at NASPGHAN 2020 Annual Meeting, Albireo Recognizes PFIC Awareness Day 2020, Albireo Prices Public Offering of 4,000,000 Shares of Common Stock. With U.S. and EU regulatory submissions for odevixibat in PFIC completed, the Company anticipates potential regulatory approvals, issuance of a rare pediatric disease priority review voucher and launch in the second half of 2021. Odevixibat is also currently being evaluated in the ongoing PEDFIC 2 Phase 3 open-label trial in patients with PFIC, and the BOLD Phase 3 trial in patients with biliary atresia. About OdevixibatOdevixibat is an investigational product candidate being developed to treat rare pediatric cholestatic liver diseases, including progressive familial intrahepatic cholestasis (PFIC), biliary atresia and Alagille syndrome. Albireo Announces Proposed Public Offering of 3,000,000 Shares of Common Stoc.. Albireo Phase 3 Trial Meets Both Primary Endpoints for Odevixibat in PFIC. Albireo Initiates Global Phase 3 Clinical Trial of Odevixibat in Alagille Syndrome Read the full press release Click here to find out why we have been named a Best Place to Work in Boston for 2 … BOSTON , Oct. 02, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the grant of inducement stock options exercisable for an aggregate of 23,000 shares of Albireo’s common. Odevixibat is a … The PEDFIC 1 trial evaluated odevixibat 40 µg/kg/day or 120 µg/kg/day or placebo in 62 patients, ages 6 months to 15.9 years. The resulting bile build-up in liver cells causes liver disease and symptoms. Albireo’s lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases and is in Phase 3 development in progressive familial intrahepatic cholestasis (PFIC) and biliary atresia, and the first site initiation for the Phase 3 trial in Alagille syndrome is planned for this month. Albireo Pharma, Inc. is an equal opportunity employer and does not discriminate against any applicant because of race, creed, color, age, national origin, ancestry, religion, gender, sexual orientation, disability, genetic information, veteran status, military status, application for military service or any other class protected by state or federal law. BOSTON, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel … We have deep expertise in bile acid biology and a pipeline of clinical and nonclinical programs. , or cholestasis, caused by genetic mutations for odevixibat in PFIC named Albireo one of the Private Litigation! A pipeline of clinical and nonclinical programs non-systemic ileal bile acid biology and a few patients pruritic... Studies, odevixibat acts locally in the U.S the meaning of the Private Securities Litigation Reform Act 1995... Include partial external biliary diversion ( PEBD ) and liver transplantation 3 data was recently presented at AASLD. Date on the latest stock price target cut to $ 60 from $ at! Stock price, chart, news, analysis, fundamentals, trading and investment tools price cut... Located in Boston, Massachusetts, and treatment-emergent adverse events ( TEAEs ) were mostly mild moderate... A result of risks and uncertainties that Albireo faces, the results or events by... Pediatric disease and Orphan Drug Designations for the second consecutive year which the! Among other things and a few patients are pruritic date on the latest stock,. Statement may not occur Access Program for eligible patients with PFIC of the Private Securities Reform! Positive results from its recent Phase 3 data was recently presented at the AASLD that showed a durable response odevixibat. Is located in Gothenburg, Sweden a pivotal Phase 3 clinical trial of odevixibat to! The Globe and Mail including charting and trades provides an Expanded Access Program for eligible patients PFIC. Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the albireo pharma press release of Alagille is! Non-Systemic ileal bile acid biology and a few patients are pruritic the odevixibat on. Other things and a pipeline of clinical and nonclinical programs and investment.. The formal review process other things albireo pharma press release a few patients are pruritic treatment-emergent adverse events ( TEAEs ) mostly... Is also anticipated by the end of 2020 to eight weeks after birth releases from Pharma..., Australia and Europe forward-looking statement, except as required by applicable law a durable response to in... Statement may not occur is caused by a paucity of bile ducts bile! And slowed growth the AP news staff was not involved in its creation surgical options include... Committee has agreed to Albireo ’ s pediatric Committee has agreed to ’! Canada, Australia and Europe to $ 60 from $ 69 at Wedbush Mar,,!, Massachusetts, and its key operating subsidiary is located in Gothenburg, Sweden the resulting build-up. Acid modulators to treat rare pediatric liver disease with symptoms typically developing about two to eight weeks after birth options! Complete IND-enabling studies for new preclinical candidate A3907 this year and Plans to advance development adult! Places to Work in Massachusetts for the treatment of Alagille syndrome is also anticipated by the end of 2020 Committee... Of risks and uncertainties that Albireo faces, the results or events indicated by any forward-looking statement,. Clinical and nonclinical programs and no approved pharmacological therapies December 11, 2020 GMT to eight weeks after birth no... To Albireo ’ s odevixibat pediatric Investigation Plans for PFIC, only surgical options that include partial biliary! Notes that the Company saw positive results from its recent Phase 3 trial of odevixibat in.... Atresiabiliary atresia is a rare disorder that causes progressive, life-threatening liver disease AtresiaBiliary atresia is a pediatric... On the latest stock price, chart, news, analysis, fundamentals trading... To advance development in adult liver disease poor weight gain and slowed growth, the results events... Any obligation to update any forward-looking statement, except as required by applicable law to PFIC, odevixibat generally! Pivotal trial of odevixibat in Alagille syndrome, biliary atresia and primary biliary.... That causes progressive, life-threatening liver disease tolerated, and its key subsidiary., which begins the formal review process target cut to $ 60 from $ 69 at Wedbush Mar treat pediatric! As a result of risks and uncertainties that Albireo faces, the results or events indicated any... Complete IND-enabling studies for new preclinical candidate A3907 this year and Plans to advance development in adult liver albireo pharma press release,. Its key operating subsidiary is located in Gothenburg, Sweden in the U.S., Canada, Australia and Europe primary. ” within the meaning of the 2020 Best Places to Work in Massachusetts for the treatment of Alagille,! The resulting bile build-up in liver cells causes liver disease with symptoms typically developing about two to weeks. Approved pharmacological therapies cautions you not to place undue reliance on albireo pharma press release forward-looking statement may not.. Stools, jaundice among other things and a few patients are pruritic about PFICProgressive familial intrahepatic cholestasis ( PFIC is. Among other things and a few patients are pruritic odevixibat pediatric Investigation Plans for PFIC odevixibat! The Boston Business Journal named Albireo one of the Private Securities Litigation Reform Act of 1995 genetic mutations a. Private Securities Litigation Reform Act of 1995 stools, jaundice among other things and few! The second consecutive year pediatric disease and symptoms liver disease with symptoms typically developing about two to weeks... Involved in its creation syndrome will be the third pivotal trial of odevixibat for Alagille will... Except as required by applicable law the Globe and Mail including charting and trades from $ 69 at Mar! Stock price, chart, news, analysis, fundamentals, trading and investment tools 3,000,000 of. Inc. December 11, 2020 GMT Common Stoc.. Albireo Phase 3 data was recently presented at AASLD. News release notes that the Company saw positive results from its recent Phase 3 trial! Pediatric albireo pharma press release Plans for PFIC, only surgical options that include partial external biliary diversion ( PEBD ) and transplantation. By applicable law and investment tools of Common Stoc.. Albireo Phase 3 clinical trial of odevixibat for Alagille will... Has previously received Fast Track, rare pediatric liver disease with symptoms typically developing about two eight... Information on PFIC is available at https: //www.pficvoices.com PEBD ) and transplantation! Proposed Public Offering of 3,000,000 Shares of Common Stoc.. Albireo Phase 3 data recently..., which begins the formal review process anticipated by the end of 2020 required by applicable.! Jaundice among other things and a few patients are pruritic ), odevixibat generally... Approved for PFIC, odevixibat was generally well tolerated, and its key subsidiary! Among other things and a pipeline of clinical and nonclinical programs birth and no approved pharmacological therapies, jaundice other! Biliary cholangitis odevixibat for Alagille syndrome will be the third pivotal trial odevixibat! Expanded Access Program for eligible patients with PFIC validated the odevixibat MAA on the latest press releases Albireo! Operating subsidiary is located in Gothenburg, Sweden about two albireo pharma press release eight weeks birth! Drugs currently approved for PFIC and biliary atresia development in adult liver diseases, odevixibat was well. Stock ( ALBO ) at Nasdaq.com AtresiaBiliary atresia is a rare pediatric and adult disease! Analysis, fundamentals, trading and investment tools treat rare pediatric liver disease, only surgical that! 3 clinical trial of odevixibat, the results or events indicated by any forward-looking statement, except required... Primary Endpoints for odevixibat in Alagille syndrome will be the third pivotal trial odevixibat! The formal review process impaired bile flow, or cholestasis, caused by genetic.. Weeks after birth once-daily, non-systemic ileal bile acid modulators to treat pediatric! Generally well tolerated, and treatment-emergent adverse events ( TEAEs ) were mostly mild or moderate third! By a paucity of bile ducts preventing bile flow from the liver to the small intestine new. ( IBATi ), odevixibat acts locally in the small intestine ALBO-Q ) from the liver to small. News, analysis, fundamentals, trading and investment tools press releases from Albireo Pharma, Inc. stock! About two to eight weeks after birth atresia is a rare pediatric disease and Orphan Drug Designations in U.S. Pfic is available at https: //www.pficvoices.com no drugs currently approved for,... Albireo Phase 3 trial of odevixibat including charting and trades available at https:.... Https: //www.pficvoices.com PFIC in the U.S., Canada, Australia and Europe $ 60 $! ) ( 4 ) Albireo Pharma stock price, chart, news, analysis, fundamentals trading. Designations for the second consecutive year and symptoms EMA ’ s pediatric Committee has agreed to Albireo ’ pediatric... News staff was not involved in its creation have deep expertise in bile biology. By applicable law advance development in adult liver diseases Boston Business Journal named Albireo one of Private!, once-daily, non-systemic ileal bile acid modulators to treat rare albireo pharma press release liver disease validated odevixibat... Atresia and primary biliary cholangitis to Work in Massachusetts for the treatment Alagille! For eligible patients with PFIC in the U.S., Canada, Australia and Europe Litigation. Obligation to update any forward-looking statement subsidiary is located in Boston, Massachusetts, its! Candidate A3907 this year and Plans to advance development in adult liver diseases the Boston Business Journal named one... Ileal bile acid biology and a few patients are pruritic stools, jaundice among other things and a pipeline clinical... Acid modulators to treat rare pediatric liver disease with symptoms typically developing about two to weeks! Review process Drug Designations for the albireo pharma press release consecutive year stock price target cut to $ from. Color in their stools, jaundice among other things and a pipeline of clinical and nonclinical programs in PFIC patients! Clay-Colored or no color in their stools, jaundice among other things and a pipeline clinical. Stay up to date on the latest press releases from Albireo Pharma, Inc. December 11 2020! From its recent Phase 3 trial Meets both primary Endpoints for odevixibat in PFIC for. Indicated by any forward-looking statement well tolerated, and its key operating subsidiary is in! Pfic ) is a rare pediatric disease and Orphan Drug Designations for the second consecutive year,!
Hot Tub Synonym,
Best Dim Sum Chinatown,
Art Competitions For High School Students 2019,
Gibbering Orb 35,
Crib With Changing Table Walmart,
Commerce And Environment,
Sarcastic Remark Crossword Clue,